Innovent Biologics has made the case that its checkpoint inhibitor-cytokine fusion protein has a future in colorectal cancer.
PT101 is an engineered IL-2 mutein fused to a protein backbone ... that are trying to flip that on its head and try to use the cytokine to protect organs from autoimmune reactions.
The Brighterside of News on MSN12h
Breakthrough cancer treatment destroys advanced-stage tumors in under 6 daysResearchers from Rice University and Baylor College of Medicine have demonstrated a groundbreaking treatment that eradicates ...
Vivtex to apply its GI-ORIS™ technology to optimize oral bioavailability of EQ302, Equillium’s novel IL-15/IL-21 bi-specific peptide ...
SON-1010 is a targeted immune activation cancer therapy designed to turn ‘cold’ tumors ‘hot’Topline safety data of SB101 Phase 1 study expected ...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to ...
19, 2024 /PRNewswire/ -- Rice University and Baylor College of Medicine have received $2.8 million in funding from the National ... of patients with hyperinflammatory ARDS. While cytokines like IL-1Ra ...
News Medical on MSN1d
Rice and Baylor receive $2.8 million to suppress inflammation and lung damage in ARDS patientsRice University and Baylor College of Medicine have received $2.8 million in funding from the National Heart, Lung, and Blood ...
IL-21-engineered NK cells offer superior safety and long-term control for glioblastoma, Merck halted 2 phase 3 KEYNOTE trials of pembrolizumab, and the MonumenTAL-1 trial data is discussed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback